Fast Track Designation

What is Fast Track Designation?

Fast Track designation is an FDA program that facilitates development and expedites review of drugs targeting serious conditions with unmet medical needs. The program provides sponsors with increased access to FDA throughout development, enabling faster resolution of scientific questions and more efficient clinical programs. For peptide therapeutics addressing conditions like severe obesity or treatment-resistant diabetes, Fast Track can significantly accelerate the path to approval.

Fast Track designation provides:

• More frequent FDA meetings and communication
• Written FDA feedback on development plans
• Eligibility for rolling review of application
• Potential priority review at submission
• Possible accelerated approval pathway

Qualifying Criteria

Serious Condition

FDA considers a condition “serious” when it has substantial impact on daily functioning or is life-threatening. Examples include:

Qualifies	May Qualify	Usually Does Not Qualify
Cancer	Moderate chronic conditions	Minor acute illnesses
Diabetes with complications	Obesity with comorbidities	Cosmetic conditions
Heart failure	Depression	Mild seasonal allergies
HIV/AIDS	Chronic pain	Minor skin conditions

Unmet Medical Need

The drug must address a need not adequately met by existing therapies:

Unmet Need	Examples
No existing treatment	Diseases with no approved therapies
Inadequate efficacy	Current treatments work poorly
Serious side effects	Existing treatments cause significant harm
Resistance	Patients stop responding to available drugs
Specific populations	Subgroups not well-served

Fast Track Benefits

Enhanced FDA Communication

Standard Development          Fast Track Development

Limited FDA interaction  →    More frequent meetings

Annual updates          →    Ongoing communication

Questions accumulate    →    Real-time guidance

Late-stage surprises    →    Early issue resolution

Rolling Review

Standard Review	Rolling Review
Complete application submitted	Sections submitted as completed
Review begins after full submission	Review begins with first section
Longer time to first feedback	Earlier identification of issues
All-or-nothing submission	Incremental progress

Eligibility for Other Programs

Fast Track designation enables access to:

• Priority Review - 6 months vs 10 months standard
• Accelerated Approval - Based on surrogate endpoints
• Breakthrough Therapy - If data supports substantial improvement

Peptide Fast Track Designations

Approved Peptides with Fast Track History

Peptide	Brand	Indication	Fast Track
Semaglutide	Wegovy	Obesity	Yes
Tirzepatide	Zepbound	Obesity	Yes
Liraglutide	Saxenda	Obesity	Yes
Setmelanotide	Imcivree	Rare obesity disorders	Yes

Peptides in Development with Fast Track

Multiple GLP-1 and multi-agonist peptides currently in development hold Fast Track designation for obesity and related metabolic conditions, reflecting FDA’s recognition of significant unmet need in these areas.

Requesting Fast Track Designation

Application Process

Identify Serious Condition + Unmet Need
                ↓
Prepare Fast Track Request
├── Disease background
├── Unmet need justification
├── Drug mechanism
├── Development plan
└── Supporting data
                ↓
Submit to FDA
                ↓
60-Day Review Period
                ↓
FDA Decision
├── Granted
├── Denied (with rationale)
└── Request more information

Timing Considerations

When to Request	Considerations
Pre-IND	Early guidance on development
After Phase 1	Safety data supports continued development
After Phase 2	Efficacy signal strengthens case
Before Phase 3	Optimize pivotal trial design

Success Factors

Strong Fast Track applications demonstrate:

• Clear definition of serious condition
• Quantified unmet need with data
• Plausible mechanism addressing the need
• Differentiation from existing treatments
• Commitment to rigorous development

Fast Track vs Other FDA Programs

Feature	Fast Track	Breakthrough	Priority Review	Accelerated
Purpose	Expedite development	Substantial improvement	Faster review	Surrogate endpoints
Stage	Development	Development	Review	Approval
Criteria	Serious + unmet need	Preliminary clinical evidence	Significant advance	Predictive surrogate
FDA meetings	Enhanced	Intensive	Standard	Standard
Rolling review	Yes	Yes	No	Yes
Review time	Priority eligible	Priority eligible	6 months	Standard/Priority

Combining Designations

Multiple designations can apply to one drug:

Fast Track (development)
        +
Breakthrough Therapy (if data supports)
        +
Priority Review (at submission)
        +
Accelerated Approval (if surrogate used)

Impact on Development Timeline

Potential Time Savings

Development Phase	Standard	With Fast Track
IND to Phase 1	12-18 months	6-12 months
Phase 2 design	Iterative	FDA-aligned
Phase 3 planning	Limited input	Ongoing dialogue
Application prep	Sequential	Rolling
Review	10 months	6 months (priority)

Real-World Example

Semaglutide for obesity:

• Fast Track designation granted
• Rolling review utilized
• Priority review at submission
• Approval in approximately 6 months from submission

Maintaining Fast Track Status

Ongoing Requirements

• Continue developing for designated indication
• Provide requested progress updates
• Maintain communication with FDA
• Report significant developments

Potential for Withdrawal

Fast Track can be rescinded if:

• Development focus shifts to different indication
• Drug no longer meets criteria
• Sponsor requests withdrawal
• Development is abandoned

Frequently Asked Questions

Does Fast Track guarantee approval?

No. Fast Track expedites development and review but doesn’t lower approval standards. The drug must still demonstrate safety and efficacy through adequate clinical trials. Many Fast Track drugs are ultimately not approved.

How common is Fast Track designation?

FDA grants Fast Track designation to hundreds of drugs annually. It’s one of the more commonly granted expedited designations. Approximately 40% of recent novel drug approvals had Fast Track designation during development.

Can Fast Track be requested after clinical trials start?

Yes. Fast Track can be requested at any time during development. However, earlier requests allow sponsors to benefit from enhanced FDA communication throughout the development program.

Is Fast Track the same as accelerated approval?

No. Fast Track is a development program providing ongoing FDA interaction and rolling review eligibility. Accelerated approval is a separate program allowing approval based on surrogate endpoints before full clinical benefit is demonstrated. A Fast Track drug may or may not use the accelerated approval pathway.

Do all obesity drugs get Fast Track?

Not automatically. Each drug must independently demonstrate it addresses a serious condition with unmet medical need. However, given the health impacts of severe obesity and limitations of current treatments, obesity drugs frequently qualify for Fast Track designation.